Global Cancer Tissue Diagnostics Industry is accelerating towards US$ 13,219 Million by 2033, fueled by healthcare infrastructure growth | FMI

Cancer Tissue Diagnostics Industry
Cancer Tissue Diagnostics Industry

The global cancer tissue diagnostics industry is expected to reach a market valuation of US$ 7,041 million by 2023, experiencing significant growth, fueled by the rising incidence of cancer and the critical role of accurate diagnosis in guiding effective treatment. According to a recent industry analysis, the market is projected to reach a value of US$ 13,219 million by 2033, representing a CAGR of 6.5% from 2023.

Cancer tissue diagnostics play a vital role in the fight against cancer, providing crucial information for accurate diagnosis, staging, and treatment planning. This market encompasses various technologies and techniques, including immunohistochemistry (IHC), in-situ hybridization (ISH), and digital pathology, which are used to analyze tissue samples for the presence and characteristics of cancer cells.

Request A Sample Copy Of This Research Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-4191

Key Drivers of Market Growth:

  • Rising Cancer Incidence: The global burden of cancer is increasing at an alarming rate, with millions of new cases diagnosed each year. This growing demand for cancer diagnosis is driving the need for advanced and reliable tissue diagnostics solutions.
  • Importance of Accurate Diagnosis: Early and accurate diagnosis is crucial for successful cancer treatment and improved patient outcomes. Tissue diagnostics offer a highly reliable method for identifying cancer type, stage, and potential treatment options.
  • Technological Advancements: Advancements in tissue diagnostics technology, such as digital pathology and artificial intelligence (AI)-powered analysis, are improving efficiency, accuracy, and accessibility of diagnostic services.

Market Trends and Opportunities:

  • Growing adoption of digital pathology: Digital pathology offers several advantages over traditional methods, including remote access, improved collaboration, and AI-powered analysis. This trend is expected to continue driving market growth in the coming years.
  • Focus on personalized medicine: The growing focus on personalized medicine is creating demand for companion diagnostics that can identify patients who are likely to respond to specific treatments. This trend is expected to fuel the development of new and targeted tissue diagnostics solutions.
  • Expansion in emerging markets: The rising healthcare expenditure and increasing awareness of cancer in developing countries are creating significant opportunities for the growth of the cancer tissue diagnostics market in these regions.

The Future of Cancer Tissue Diagnostics:

The cancer tissue diagnostics market is poised for continued growth in the coming years, driven by the rising burden of cancer, the increasing importance of accurate diagnosis, and advancements in technology. The development of new and innovative solutions, such as AI-powered analysis and personalized diagnostics, is expected to further propel market growth and improve patient outcomes.

Top Highlights from the FMI’s Analysis of the Cancer Tissue Diagnostics Market:

  • North America and Europe are the highly penetrated markets for cancer tissue diagnostics. FMI has estimated that these markets are expected to surpass market values of 38.9% and 30.1%, respectively, in 2023.
  • The United States and Germany are the key markets with assessed value shares of 32.6% and 4.5%, respectively, in 2022. Globally as well as regionally, these markets top the charts.
  • China and India are projected to propel at a CAGR of 7.5% and 6.4%, correspondingly. Manufacturers are focusing on emerging economies to generate higher revenues as established markets reach saturation.
  • Australia is expected to witness a strong CAGR over the forecast period. As per FMI intelligence, the market is projected to shoot at a CAGR of 10.3% from 2023 to 2033, implying a booming economy, robust cancer cases, and surging acceptance of cancer tissue diagnostics.
  • According to FMI, Japan is anticipated to attain more than 5.2% market share in the forecast period.
  • Based on test type, in situ hybridization segment acquired a market share of 62.9% in 2022.
  • Under the end-user category, the hospital-associated labs segment obtained a 44.2% value share in 2022.

Get In Touch With Our Analyst To Resolve Any Doubts You May Have! https://www.futuremarketinsights.com/ask-question/rep-gb-4191

Global Cancer Tissue Diagnostics Market Key Players:

  • Abbott Laboratories
  • F.Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Ventana Medical Systems, Inc.
  • Bio Rad Laboratories Inc.
  • Enzo Life Sciences, Inc.
  • Abcam plc.
  • BioGenex
  • Cell Signalling Technology, Inc.
  • Agilent Technologies, Inc.
  • PerkinElmer Inc.

Personalized Experiences Redefined: Our Customization Report Holds the Answers! https://www.futuremarketinsights.com/customization-available/rep-gb-4191

Cancer Tissue Diagnostics Market by Segmentation:

By Test Type:

  • Immunohistochemical (IHC) Test
    • Breast Cancer
    • Stomach (Gastric) Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Others
  • In Situ Hybridization (ISH) Test
    • Breast Cancer
    • Non-Small Cell Lung Cancer (NSCLC)
    • Bladder Cancer
    • Others

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East & Africa (MEA)

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: 
sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

About the Author

Ronak Shah

Associate Vice President at Future Market Insights is deeply committed to uncovering actionable insights for consumer and food and beverage players. She brings a unique blend of analysis, industry trends, and consumer behavior to put data into perspective.

What she makes out of data becomes a delight to read. She has authored many opinions, including for publications like Process Industry Informer and Spinal Surgery News, as she understands the market pulse and consumers' shifting preferences.

She likes to bring experts to a roundtable to weigh the impact of a trend on an industry. Catch up with her discussion on the impact of AI in packaging.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these